<p>摩根大通（NASDAQ:MRUS - 获取免费报告）的股票在周二发布的一份报告中，美国银行的股票研究分析师重申了其&#34;买入&#34;评级，据 Benzinga 报道。他们目前对这家生物技术公司的股票设定了 76.00 美元的目标价。美国银行的目标价表明，该股从上一个交易日收盘价上涨了 35.52% 的潜在空间。</p>
<p>MRUS 已成为关注的对象。Guggenheim 将 Merus 的目标价从 57.00 美元上调至 93.00 美元，并在 5 月 28 日星期二的研究报告中给予该股票&#34;买入&#34;评级。Stifel Nicolaus 将 Merus 的目标价从 90.00 美元上调至 99.00 美元，并在 6 月 17 日星期一的报告中给予该股票&#34;买入&#34;评级。Canaccord Genuity Group 将 Merus 的目标价从 54.00 美元上调至 67.00 美元，并在 6 月 4 日星期二的报告中给予该股票&#34;买入&#34;评级。BMO Capital Markets 将 Merus 的目标价从 84.00 美元上调至 91.00 美元，并在 6 月 4 日星期二的报告中给予该公司&#34;表现优异&#34;评级。最后，William Blair 在 4 月 22 日星期一的报告中重申了对 Merus 的&#34;表现优异&#34;评级。一位投资分析师对该股票进行了卖出评级，而其他十二位分析师则给予该公司买入评级。根据 MarketBeat.com 的数据，Merus 的共识评级为&#34;中度买入&#34;，平均目标价为 73.60 美元。</p>
<p><strong>阅读我们关于 Merus 的最新报告</strong></p>
<h2>Merus 股票表现</h2>
<p>MRUS 股票周二在盘中交易中下跌 0.83 美元，报 56.08 美元。该股的成交量为 310,287 股，相比平均成交量 786,509 股有所下降。Merus 的一年最低价为 19.81 美元，最高价为 61.61 美元。该股的市值为 32.9 亿美元，市盈率为-20.25，β系数为 1.10。该公司的 50 天移动平均价格为 49.06 美元，200 天移动平均价格为 42.06 美元。</p>
<p>Merus（NASDAQ:MRUS - 获取免费报告）上次公布其财报是在 5 月 8 日星期三。这家生物技术公司报告该季度每股亏损（EPS）为 0.59 美元，超过分析师预期的 0.83 美元。该公司在该季度实现了 7.89 百万美元的收入，低于分析师预期的 8.94 百万美元。Merus 的净利润率为-390.36%，净资产收益率为-44.13%。平均而言，股票分析师预计 Merus 在本财年将实现-3.1 美元的每股收益。</p>
<h2>Merus 内部交易</h2>
<p>另外，副总裁 Harry Shuman 于 6 月 10 日星期一进行了一笔交易，卖出了该公司 1000 股股票。该股票的平均价格为 53.22 美元，交易总额为 53,220.00 美元。交易完成后，副总裁现在直接持有公司股票 7,002 股，价值 372,646.44 美元。该交易已在提交给美国证券交易委员会的文件中披露，可以通过此链接访问。在过去的九十天里，内部人士已经卖出了价值 792,792 美元的 14,300 股公司股票。目前公司股票的 4.57% 由内部人士持有。</p>
<h2>对 Merus 的对冲基金的看法</h2>
<p>一些机构投资者和对冲基金最近增加或减少了他们对 MRUS 的持股。Price T Rowe Associates Inc. MD 在第一季度购入了 Merus 的新股，价值约 53,377,000 美元。RTW Investments LP 在第三季度将其对 Merus 的持股增加了 90.0%。RTW Investments LP 现在拥有 1,996,764 股该生物技术公司的股票，价值 47,084,000 美元，较上一季度增加了 945,871 股。Deerfield Management Company L.P. Series C 在第三季度将其对 Merus 的持股增加了 27.9%。Deerfield Management Company L.P. Series C 现在拥有 3,876,938 股该生物技术公司的股票，价值 91,418,000 美元，较上一季度增加了 845,000 股。Federated Hermes Inc.在第四季度将其对 Merus 的持股增加了 26.0%。Federated Hermes Inc.现在拥有 3,637,309 股该生物技术公司的股票，价值 100,026,000 美元，较上一季度增加了 751,609 股。最后，Artal Group S.A.在第一季度购入了 Merus 的新股，价值约 20,492,000 美元。目前公司股票的 96.14% 由机构投资者和对冲基金持有。</p>
<h2>关于 Merus（获取免费报告）</h2>
<p>Merus N.V.是一家总部位于荷兰的临床阶段免疫肿瘤学公司，致力于开发抗体治疗。其双特异性抗体候选药物包括 Zenocutuzumab（MCLA-128），目前正在进行 II 期临床试验，用于治疗转移性乳腺癌和去势抵抗性前列腺癌患者，以及正在进行 I/II 期临床试验，用于治疗携带神经生长因子 1 的实体瘤。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只比 Merus 更好的股票</li>
<li>投资中的降级意味着什么？</li>
<li>Chipotle Mexican Grill 股票拆分：未来走向何方？</li>
<li>股市板块：它们是什么，有多少种？</li>
<li>Arm Holdings 和 Micron：两大 AI 股票</li>
<li>沃伦·巴菲特推荐的 3 只股票</li>
<li>在假日季节之前最好购买百思买股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw"/></p>
<p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 预计银价将出现极端价格波动（来自 Colonial Metals）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mzcw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mzcw"/></p>
<h2>现在是否值得投资 1000 美元购买 Merus 股票？</h2>
<p>在考虑 Merus 之前，您可能会想听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场意识到... 而 Merus 并不在这份名单上。</p>
<p>虽然 Merus 目前在分析师中有一个&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

药明康德

<p>美国银行已经重申对 Merus（NASDAQ: MRUS）股票的 “买入” 评级，并设定了 76.00 美元的价格目标。这是继高盛、斯蒂弗尼古拉斯、Canaccord Genuity Group、BMO 资本市场和威廉布莱尔发布其他报告后的最新消息，它们都给予了积极的评级。Merus 股票的共识评级为 “中度买入”，平均价格目标为 73.60 美元。该股票以 56.08 美元交易，与前一交易日收盘价相比，有 35.52% 的潜在上涨空间</p>

<p>Merus (NASDAQ:MRUS - Get Free Report)'s stock had its &#34;buy&#34; rating reiterated by equities research analysts at Bank of America in a report released on Tuesday, Benzinga reports. They presently have a $76.00 price objective on the biotechnology company's stock. Bank of America's target price points to a potential upside of 35.52% from the stock's previous close.</p>
<div class="lb-trans"><p>摩根大通（NASDAQ:MRUS - 获取免费报告）的股票在周二发布的一份报告中，美国银行的股票研究分析师重申了其&#34;买入&#34;评级，据 Benzinga 报道。他们目前对这家生物技术公司的股票设定了 76.00 美元的目标价。美国银行的目标价表明，该股从上一个交易日收盘价上涨了 35.52% 的潜在空间。</p>
</div><p>MRUS has been the subject of a number of other reports. Guggenheim upped their price objective on shares of Merus from $57.00 to $93.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, May 28th. Stifel Nicolaus boosted their target price on shares of Merus from $90.00 to $99.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, June 17th. Canaccord Genuity Group boosted their target price on shares of Merus from $54.00 to $67.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, June 4th. BMO Capital Markets upped their price objective on shares of Merus from $84.00 to $91.00 and gave the company an &#34;outperform&#34; rating in a report on Tuesday, June 4th. Finally, William Blair restated an &#34;outperform&#34; rating on shares of Merus in a report on Monday, April 22nd. One investment analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, Merus has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $73.60.</p>
<div class="lb-trans"><p>MRUS 已成为关注的对象。Guggenheim 将 Merus 的目标价从 57.00 美元上调至 93.00 美元，并在 5 月 28 日星期二的研究报告中给予该股票&#34;买入&#34;评级。Stifel Nicolaus 将 Merus 的目标价从 90.00 美元上调至 99.00 美元，并在 6 月 17 日星期一的报告中给予该股票&#34;买入&#34;评级。Canaccord Genuity Group 将 Merus 的目标价从 54.00 美元上调至 67.00 美元，并在 6 月 4 日星期二的报告中给予该股票&#34;买入&#34;评级。BMO Capital Markets 将 Merus 的目标价从 84.00 美元上调至 91.00 美元，并在 6 月 4 日星期二的报告中给予该公司&#34;表现优异&#34;评级。最后，William Blair 在 4 月 22 日星期一的报告中重申了对 Merus 的&#34;表现优异&#34;评级。一位投资分析师对该股票进行了卖出评级，而其他十二位分析师则给予该公司买入评级。根据 MarketBeat.com 的数据，Merus 的共识评级为&#34;中度买入&#34;，平均目标价为 73.60 美元。</p>
</div><p><strong>Read Our Latest Report on Merus</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Merus 的最新报告</strong></p>
</div><h2>Merus Stock Performance</h2>
<div class="lb-trans"><h2>Merus 股票表现</h2>
</div><p>MRUS stock traded down $0.83 during mid-day trading on Tuesday, reaching $56.08. 310,287 shares of the stock traded hands, compared to its average volume of 786,509. Merus has a one year low of $19.81 and a one year high of $61.61. The stock has a market capitalization of $3.29 billion, a PE ratio of -20.25 and a beta of 1.10. The business has a 50-day moving average price of $49.06 and a two-hundred day moving average price of $42.06.</p>
<div class="lb-trans"><p>MRUS 股票周二在盘中交易中下跌 0.83 美元，报 56.08 美元。该股的成交量为 310,287 股，相比平均成交量 786,509 股有所下降。Merus 的一年最低价为 19.81 美元，最高价为 61.61 美元。该股的市值为 32.9 亿美元，市盈率为-20.25，β系数为 1.10。该公司的 50 天移动平均价格为 49.06 美元，200 天移动平均价格为 42.06 美元。</p>
</div><p>Merus (NASDAQ:MRUS - Get Free Report) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.24. The firm had revenue of $7.89 million during the quarter, compared to analyst estimates of $8.94 million. Merus had a negative net margin of 390.36% and a negative return on equity of 44.13%. On average, equities analysts expect that Merus will post -3.1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Merus（NASDAQ:MRUS - 获取免费报告）上次公布其财报是在 5 月 8 日星期三。这家生物技术公司报告该季度每股亏损（EPS）为 0.59 美元，超过分析师预期的 0.83 美元。该公司在该季度实现了 7.89 百万美元的收入，低于分析师预期的 8.94 百万美元。Merus 的净利润率为-390.36%，净资产收益率为-44.13%。平均而言，股票分析师预计 Merus 在本财年将实现-3.1 美元的每股收益。</p>
</div><h2>Insider Transactions at Merus</h2>
<div class="lb-trans"><h2>Merus 内部交易</h2>
</div><p>In other news, VP Harry Shuman sold 1,000 shares of the business's stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $53.22, for a total transaction of $53,220.00. Following the completion of the transaction, the vice president now directly owns 7,002 shares of the company's stock, valued at $372,646.44. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders sold 14,300 shares of company stock valued at $792,792. 4.57% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>另外，副总裁 Harry Shuman 于 6 月 10 日星期一进行了一笔交易，卖出了该公司 1000 股股票。该股票的平均价格为 53.22 美元，交易总额为 53,220.00 美元。交易完成后，副总裁现在直接持有公司股票 7,002 股，价值 372,646.44 美元。该交易已在提交给美国证券交易委员会的文件中披露，可以通过此链接访问。在过去的九十天里，内部人士已经卖出了价值 792,792 美元的 14,300 股公司股票。目前公司股票的 4.57% 由内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On Merus</h2>
<div class="lb-trans"><h2>对 Merus 的对冲基金的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRUS. Price T Rowe Associates Inc. MD purchased a new stake in Merus in the first quarter valued at approximately $53,377,000. RTW Investments LP raised its stake in shares of Merus by 90.0% during the third quarter. RTW Investments LP now owns 1,996,764 shares of the biotechnology company's stock worth $47,084,000 after purchasing an additional 945,871 shares during the last quarter. Deerfield Management Company L.P. Series C raised its stake in shares of Merus by 27.9% during the third quarter. Deerfield Management Company L.P. Series C now owns 3,876,938 shares of the biotechnology company's stock worth $91,418,000 after purchasing an additional 845,000 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of Merus by 26.0% during the fourth quarter. Federated Hermes Inc. now owns 3,637,309 shares of the biotechnology company's stock worth $100,026,000 after purchasing an additional 751,609 shares during the last quarter. Finally, Artal Group S.A. purchased a new stake in shares of Merus during the first quarter worth approximately $20,492,000. 96.14% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了他们对 MRUS 的持股。Price T Rowe Associates Inc. MD 在第一季度购入了 Merus 的新股，价值约 53,377,000 美元。RTW Investments LP 在第三季度将其对 Merus 的持股增加了 90.0%。RTW Investments LP 现在拥有 1,996,764 股该生物技术公司的股票，价值 47,084,000 美元，较上一季度增加了 945,871 股。Deerfield Management Company L.P. Series C 在第三季度将其对 Merus 的持股增加了 27.9%。Deerfield Management Company L.P. Series C 现在拥有 3,876,938 股该生物技术公司的股票，价值 91,418,000 美元，较上一季度增加了 845,000 股。Federated Hermes Inc.在第四季度将其对 Merus 的持股增加了 26.0%。Federated Hermes Inc.现在拥有 3,637,309 股该生物技术公司的股票，价值 100,026,000 美元，较上一季度增加了 751,609 股。最后，Artal Group S.A.在第一季度购入了 Merus 的新股，价值约 20,492,000 美元。目前公司股票的 96.14% 由机构投资者和对冲基金持有。</p>
</div><h2>About Merus (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Merus（获取免费报告）</h2>
</div><p>Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.</p>
<div class="lb-trans"><p>Merus N.V.是一家总部位于荷兰的临床阶段免疫肿瘤学公司，致力于开发抗体治疗。其双特异性抗体候选药物包括 Zenocutuzumab（MCLA-128），目前正在进行 II 期临床试验，用于治疗转移性乳腺癌和去势抵抗性前列腺癌患者，以及正在进行 I/II 期临床试验，用于治疗携带神经生长因子 1 的实体瘤。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Merus</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Chipotle Mexican Grill Stock Split: Where Does it Go From Here?</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>Arm Holdings and Micron: Top 2 AI Stocks to Buy and Hold</li>
<li>3 Warren Buffett Stocks to Buy Now</li>
<li>Best Buy Stock May Be Best Bought Before the Holiday Season</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只比 Merus 更好的股票</li>
<li>投资中的降级意味着什么？</li>
<li>Chipotle Mexican Grill 股票拆分：未来走向何方？</li>
<li>股市板块：它们是什么，有多少种？</li>
<li>Arm Holdings 和 Micron：两大 AI 股票</li>
<li>沃伦·巴菲特推荐的 3 只股票</li>
<li>在假日季节之前最好购买百思买股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVJVUw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=MRUS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Silver Expected for Extreme Price Action (From Colonial Metals)(Ad)</p>
<div class="lb-trans"><p>→ 预计银价将出现极端价格波动（来自 Colonial Metals）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04Mzcw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8370&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Merus right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买 Merus 股票？</h2>
</div><p>Before you consider Merus, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Merus 之前，您可能会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，然后等待整个市场意识到... 而 Merus 并不在这份名单上。</p>
</div><p>While Merus currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Merus 目前在分析师中有一个&#34;买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Merus (NASDAQ:MRUS) Stock Rating Reaffirmed by Bank of America

1. 核心描述性事实信息：
   - Merus（NASDAQ: MRUS）的股票在周二的一份报告中被美国银行的股票研究分析师重申为 “买入” 评级。
   - 美国银行目前对这家生物技术公司的股票设定了 76.00 美元的目标价。
   - 美国银行的目标价表明，该股的潜在上涨空间为 35.52%。
2. 观点与支撑逻辑：
   - 多家研究机构对 Merus 的股票进行了评级和目标价调整，普遍看好该公司的发展前景。
   - Bank of America、Guggenheim、Stifel Nicolaus 和 Canaccord Genuity Group 等机构纷纷给予 Merus 股票 “买入” 评级，并上调了目标价，显示出市场对 Merus 未来增长的乐观态度。
   - 这些研究机构的看法和调整目标价的行为可能受到 Merus 公司业绩表现、产品前景、行业发展趋势等因素的影响，表明市场对 Merus 的投资价值持续看好。

药明康德（NASDAQ:MRUS）股票评级被美国银行重申